NCT05351801View on ClinicalTrials.gov

Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Diabetic Neuropathic PainPeripheral Neuropathic Pain
Interventions
DRUG

THC (Syndros)

Participants will receive a target dose of 10mg per day of THC (Syndros).

DRUG

CBD (Epidolex)

Participants will receive a target dose of 800 mg per day of CBD (Epidolex).

DRUG

THC + CBD (Nabiximols)

Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).

DRUG

Placebo

Placebo

Trial Locations (5)

92161-0002

RECRUITING

VA San Diego Healthcare System, San Diego, CA, San Diego

06516-2770

RECRUITING

VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven

02908-4734

RECRUITING

Providence VA Medical Center, Providence, RI, Providence

78229-4404

RECRUITING

South Texas Health Care System, San Antonio, TX, San Antonio

98108-1532

TERMINATED

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

All Listed Sponsors
lead

VA Office of Research and Development

FED